{"id":"NCT00566020","sponsor":"GlaxoSmithKline","briefTitle":"A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -","officialTitle":"Study SCA106052, a Clinical Evaluation of BW430C (Lamotrigine) in Bipolar I Disorder- Long-term Extension Study (Extension of Study SCA104779 (NCT00550407))","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2007-11-30","resultsPosted":"2011-07-27","lastUpdate":"2017-04-04"},"enrollment":92,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"BW430C (lamotrigine)","otherNames":[]}],"arms":[{"label":"Lamotrigine","type":"EXPERIMENTAL"}],"summary":"This study is planned to assess the long-term safety of lamotrigine in Japanese patients with bipolar I disorder who will continue into the 52-week extension upon completion of a double-blind comparative study (Study No.: SCA104779 (NCT00550407)), i.e. the patients who receive the addition of any additional treatment to intervene in a mood episode in the double-blind phase or the patients completing the double-blind phase.","primaryOutcome":{"measure":"Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event","timeFrame":"From baseline (Week 0) until 2 weeks after the end of treatment (Week 54)","effectByArm":[{"arm":"Lamotrigine","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":52,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":92},"commonTop":["Nasopharyngitis","Abdominal pain upper","Stomatitis","Nausea","Vomiting"]}}